share_log

Regeneron Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Thompson Craig B.

Regeneron Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Thompson Craig B.

再生元制药公司 | 4:持股变动声明-董事 Thompson Craig B.
美股SEC公告 ·  01/07 05:13

Moomoo AI 已提取核心信息

On January 2, 2025, Thompson Craig B., associated with Regeneron Pharmaceuticals, acquired 166 shares of Common Stock at $0 per share through a grant or award. This transaction was reported as completed.Following the acquisition, Thompson Craig B.'s direct ownership of Regeneron's Common Stock increased to 620 shares. The shares were acquired under a 'Direct' ownership form, indicating personal ownership rather than through an intermediary or related entity.
On January 2, 2025, Thompson Craig B., associated with Regeneron Pharmaceuticals, acquired 166 shares of Common Stock at $0 per share through a grant or award. This transaction was reported as completed.Following the acquisition, Thompson Craig B.'s direct ownership of Regeneron's Common Stock increased to 620 shares. The shares were acquired under a 'Direct' ownership form, indicating personal ownership rather than through an intermediary or related entity.
在2025年1月2日,汤普森·克雷格(Thompson Craig b.),与再生元制药公司(Regeneron Pharmaceuticals)有关,获得了166股普通股,每股价格为0美元,通过授予或奖励完成了此次交易。该交易已报告完成。完成此次收购后,汤普森·克雷格(Thompson Craig b.)直接持有的再生元的普通股增加至620股。这些股份是以“直接”所有权的形式获得,表示个人所有权,而非通过中介或关联实体。
在2025年1月2日,汤普森·克雷格(Thompson Craig b.),与再生元制药公司(Regeneron Pharmaceuticals)有关,获得了166股普通股,每股价格为0美元,通过授予或奖励完成了此次交易。该交易已报告完成。完成此次收购后,汤普森·克雷格(Thompson Craig b.)直接持有的再生元的普通股增加至620股。这些股份是以“直接”所有权的形式获得,表示个人所有权,而非通过中介或关联实体。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息